Comparison Of Chemotherapy And Chemoradiotherapy For Treatment Of Locally Advanced Inoperable Stage-Ⅲ Non-small Cell Lung Cancer

Objective: To retrospectively analyze the efficacy and toxicity of treatment with chemotherapy, chemoradiotherapy in locally advanced inoperable stage-IIInon-small cell lung cancer. Methods: 80 patients with histologically or cytologically confirmed locally advanced non-small cell lung cancer (LANSCLC) from January 2002 to January 2004 were analyzed retrospectively. The Patients were not treated previously and their KPS was≥70. They were divided into two treatment groups:(l) chemotherapy only (45patients) , 17 received the second generation of platinum-based regimens, 28 received the third generation;(2) chemoradiotherapy combination(35 patients), 35 patients received 3-dimensional conformal radiotherapy( 3D-CRT). Results: (1) The effective rates were 41.17% in the second generation group, and 53.57% in the third generation group (P<0.05) . The median time to progression and response rates were significantly longer in the third generation group than in the second generation group (P<0.05);(2) The median survival time and 1- ,2-and 3-year survival rates were 8.6 months, 22.22 %, 17.78% and 0 respectively in the chemotherapy group;14.5months, 42.86%,37.14% and 5.71%, respectively in the combination therapy group.(3) The major adverse events were leukocytopenia, nausea and vomiting, which were tolerable. Conclusion: (1) The third generation of platinum-based regimens for advanced non-small lung cancer may be more advantageous over the second generation of platinum-based regimens in effective rates and the median time to progression on advanced NSCLC patients, which would be worth being studied further. (2) Significantly favorable results were obtained in the combination therapy group.